Reata's bardoxolone offers promise in patients with rare kidney disorder

Reata's bardoxolone offers promise in patients with rare kidney disorder

Source: 
Endpoints
snippet: 

After surprising Wall Street with positive data on its drug, omaveloxolone, in patients suffering from a notoriously hard-to-treat degenerative neuromuscular disorder last month, Reata Pharma on Monday unveiled pivotal results from a trial testing another drug, bardoxolone, in patients with a rare, genetic form of chronic kidney disease for which there exist no approved therapies.